AS703569 and Gemcitabine Combination in Advanced Malignancies
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
In clinical practice and research, combination of anticancer agents is often used to improve
efficacy of treatment. In vitro and in vivo experiments have shown additive-synergistic
anti-tumour effects of AS703569 treatment when combined with gemcitabine. Specifically,
additive-synergistic anti-tumour effects were noticed when the two agents were given
sequentially and not concomitantly i.e. AS703569 given the day before or the day after
gemcitabine. This trial was designed to investigate in parallel two regimens testing
sequential administration of AS703569 either the day after gemcitabine infusion, (Regimen 1)
or the day before (Regimen 2).